Efficacy of risk reductioninterventions on number

Publication	No. of sexual partners (Mean(SD)) or proportion of multiple sexual partners (%)		Drug use or needle sharing (% or Mean(SD))		Alcoholabuse * (% or Mean(SD))
Publication	IG	CG	IG	CG	IG	CG
Kelly et al. [32]	N/A	N/A	Drug use I1: 70.4→55.6 ^PM3,F3 I2: 64.3→64.3 ^PM3,F3	Drug use 63.0→63.0 ^PM3,F3	I1: 88.9→88.9 ^PM3,F3 I2: 92.9→78.6 ^PM3,F3	85.2→85.2 ^PM3,F3
Kalichman et al. [37]	AP^PM3 1.6(2.4)→1.3(2.3)^PM3,F3 1.6(2.4)→1.2(1.9)^PM3,F6	AP^PM3 1.7(3.3)→1.2(1.5)^PM3,F3 1.7(3.3)→1.3(1.9)^PM3,F6	N/A	N/A	N/A	N/A
Margolin et al. [23]	N/A	N/A	Needle sharing 44.4→12.9 ^PM1,F0 44.4→11.8 ^PM1,F3	Needle sharing 53.3→22.6 ^PM1,F0 53.3→10.7 ^PM1,F3	N/A	N/A
Sorensen et al.[38]	N/A	N/A	Drug use 0.2(0.13)→0.2(0.14)^PM1,F6 0.2(0.13)→0.2(0.13)^PM1,F12 0.2(0.13)→0.1(0.10)^PM1,F18 Needle sharing 1.2(0.99)→0.6(0.84) ^PM1,F6 1.2(0.99) → 0.7(0.90) ^PM1,F12 1.2(0.99) → 0.3(0.65) ^PM1,F18	Drug use 0.2(0.13)→0.2(0.13)^PM1,F6 0.2(0.13)→0.1(0.12)^PM1,F12 0.2(0.13)→0.1(0.10)^PM1,F18 Needle sharing 1.2(1.06)→0.7(0.98) ^PM1,F6 1.2(1.06)→0.8(1.04) ^PM1,F12 1.2(1.06)→0.5(0.89) ^M1,F18	0.2(0.25→0.2(0.22) ^PM1,F6 0.2(0.25→0.1(0.18) ^PM1,F12 0.2(0.25→0.1(0.16)^PM1,F18	0.2(0.26→0.2(0.22) ^PM1,F6 0.2(0.26→0.2(0.23) ^PM1,F12 0.2(0.26→0.1(0.19) ^PM1,F18
Purcell et al. [39]	N/A	N/A	Needle sharing for HNUP 28.6→9.7 ^PM3,F3 28.6→7.3 ^PM3,F6 28.6→5.8 ^PM3,F12	Needle sharing for HNUP 28.9→12.0 ^PM3,F3 28.9→10.6 ^PM3,F6 28.9→6.6 ^PM3,F12	N/A	N/A
Gilbert et al. [24]	CP^PM3 -2.3(9.2)^F3 -2.7(8.4)^F6	CP^PM3 -1.4(7.9)^F3 -0.6(5.6)^F6	Drug use 43.8→38.5^PM3,F3 43.8→29.5^PM3,F6	Drug use 41.1→41.5^PM3,F3 41.1→42.5^PM3,F6	Any risk drinking² 38.3→26.4 ^PM3,F3 38.3→23.5 ^PM3,F6	Any risk drinking² 39.0→29.8^PM3,F3 39.0→27.5^PM3,F6
Williams et al. [40]	AP^PM6 6.69(1.43)→3.46(0.51)^F0 6.69(1.43)→2.34(0.47) ^F36.69(1.43)→1.69(0.19)^F6	AP^PM6 5.49(1.32)→3.49(0.47)^F05. 49(1.32)→3.12(0.43^)F35. 49(1.32)→1.71(0.17)^F6	N/A	N/A	N/A	N/A
Coleman et al. [41]	AP^PM3 81.8→45.0^F3	AP^PM3 78.6→53.9^F3	N/A	N/A	N/A	N/A
Rose et al. [8]	AP^PM6 5.2(16.3)→ 4.3(9.9)F6 HNUP^PM6 3.1(3.8)→ 1.5(2.0)^F6	AP^PM6 4.6(16.0)→ 8.1(67.3)F6 HNUP^PM6 2.3(2.3)→0.8(1.2)^F6	N/A	N/A	N/A	N/A
Teti et al. [22]	AP^PM6 2.50(4.36)→4.57(16.66)^F6 2.50(4.36)→1.50(0.81)^F12 2.50(4.36)→1.40(0.84)^F18	AP^PM6 2.24(3.52)→5.15(15.91)^F6 2.24(3.52)→2.77(4.39)^F12 2.24(3.52)→1.40(1.30)^F18	N/A	N/A	N/A	N/A
Wolitski et al. [9]	AP^PM3 27.2→22.6^F6 27.2→20.6^F12 27.2→24.3^F18	AP^PM3 29.2→20.9^F6 29.2→21.1^F12 29.2→21.1^F18	N/A	N/A	N/A	N/A
Kalichman et al. [20]	HNUP^PM3 0.6(1.8)→0.5(1.4)^F3 0.6(1.8)→0.6(1.1)F6 0.6(1.8)→0.04(0.6)^F9	HNUP^PM3 0.7(3.1)→0.6(1.3)^F3 0.7(3.1)→0.9(5.1)F6 0.7(3.1)→0.4(0.6)^F9	N/A	N/A	N/A	N/A

Note: IG: intervention group; CG: control groups; SD: standard deviation; AP: any partners; HNUP: HIV-negative or unknown partners; IDU: injection drug use; DU: drug users; I1: cognitive-behavioral group intervention; I2: social support group intervention; N/A: not available;
*Alcohol abuse was defined as exceeding the US National Institute on Alcoholism and Alcohol Abuse’s recommended numbers of drinks per week (14 or fewer for men; 7 or fewer for women) and or 3 or more binge drinking pisodes (5 or more drinks on 1 occasion for men; 4 or more drinks on 1 occasion for women).
^PM1: In the past month; ^PM3: In the past 3 months; ^PM6: In the past 6 months;
^F0: Immediately after intervention; ^F3: At 3-month follow-up; ^F6: At 6-month follow-up; ^F9: At 9-month follow-up; ^F12: At12-month follow-up; ^F18: At 18-month follow-up.

Table 3: Efficacy of risk reductioninterventions on number of sexual partners and drug and alcohol abuse among persons living with HIV/AIDS.

Goto home»